Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
ATTAIN-1 (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
The prescribing and dispensing are handled by independent licensed physicians and separate licensed pharmacies
TZP reduced serum creatinine (sCR), blood urea nitrogen (BUN), and advanced glycosylation end products (AGEs) levels, while simultaneously promoting insulin secretion in diabetic mice
Trava ships with cold packs to maintain appropriate temperatures
Injection site reactions typically resolve within 24 to 48 hours per injection
US$ 27.67
US$ 20.65
US$ 22.27
US$ 24.20
US$ 22.87
US$ 20.33
US$ 25.02
US$ 27.42
